We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAston Martin Lagonda Regulatory News (AML)

Share Price Information for Aston Martin Lagonda (AML)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 157.40
Bid: 156.60
Ask: 157.40
Change: 1.40 (0.90%)
Spread: 0.80 (0.511%)
Open: 157.40
High: 157.70
Low: 155.80
Prev. Close: 156.00
AML Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Satisfaction of Antitrust Conditions

26 Nov 2020 09:31

RNS Number : 6113G
Aston Martin Lagonda Global Hld PLC
26 November 2020
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE UNLAWFUL.

 

FURTHER, THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND IS NOT AN OFFER OF SECURITIES IN ANY JURISDICTION.

 

26 November 2020

 

Aston Martin Lagonda Global Holdings plc

Announcement of satisfaction of the Antitrust Conditions in relation to the Strategic Cooperation Agreement

 

Further to the announcement on 27 October 2020 by Aston Martin Lagonda Global Holdings plc (the "Company" or "Aston Martin Lagonda") relating to the Strategic Cooperation Agreement, and the publication on 18 November 2020 of the combined prospectus and circular (the "Prospectus"), the Company is pleased to announce that the Antitrust Conditions set out in the Prospectus in relation to the Strategic Cooperation Agreement have now been satisfied. Accordingly, the Strategic Cooperation is now conditional only on approval by Shareholders of the Transaction Resolutions proposed at the General Meeting of the Company to take place on 4 December 2020, as convened by the notice of meeting set out in the Prospectus.

 

Shareholders are requested to refer to the letter of recommendation from the Executive Chairman, set out in Part 5 (Letter from the Executive Chairman of Aston Martin Lagonda Global Holdings plc) of the Prospectus, which details why the Board believes the Transaction and the Resolutions to be in the best interests of the Shareholders as a whole.

 

The defined terms set out in the Prospectus apply in this Announcement.

 

Enquiries

Investors and Analysts

Charlotte Cowley Director of Investor Relations +44 (0)7771 976764

charlotte.cowley@astonmartin.com

Media

Kevin Watters Director of Communications +44 (0)7764 386683

kevin.watters@astonmartin.com

Grace Barnie Corporate Communication Manager +44 (0)7880 903490

grace.barnie@astonmartin.com

Tulchan Communications

Harry Cameron and Simon Pilkington +44 (0)20 73534200

 

Barclays (Sponsor and Financial Adviser)

Derek Shakespeare +44 (0)20 7623 2323

Enrico Chiapparoli

Tom Macdonald

Darren Johnson

 

J.P. Morgan Cazenove (Financial Adviser)

Robert Constant +44 (0)20 7742 4000

James A. Kelly

Will Holyoak

 

IMPORTANT NOTICE

 

This announcement has been issued by and is the sole responsibility of the Company. The information contained in this announcement is for background purposes only and does not purport to be full or complete. No reliance may or should be placed by any person for any purpose whatsoever on the information contained in this announcement or on its accuracy or completeness. The information in this announcement is subject to change.

 

This announcement is not a prospectus and is for information purposes only. Neither this announcement nor anything contained in it shall form the basis of, or be relied upon in conjunction with, any offer or commitment whatsoever in any jurisdiction.

 

A copy of the Prospectus is available on the Company's website at https://www.astonmartinlagonda.com/investors/October-2020-Placing. Neither the content of the Company's website nor any website accessible by hyperlinks on the Company's website is incorporated in, or forms part of, this announcement.

 

This announcement does not contain or constitute an offer for sale or the solicitation of an offer to purchase securities in the United States. None of the securities referred to in this announcement or in the Prospectus have been or will be registered under the US Securities Act of 1933 (the "Securities Act") or under any securities laws of any state or other jurisdiction of the United States and may not be offered, sold, taken up, exercised, resold, transferred or delivered, directly or indirectly, within the United States except pursuant to an applicable exemption from or in a transaction not subject to the registration requirements of the Securities Act and in compliance with any applicable securities laws of any state or other jurisdiction of the United States. There will be no public offer of any such securities in the United States. None of the securities referred to in this announcement or in the Prospectus, nor the Form of Proxy, this announcement or any other document connected with the matters discussed in this announcement or in the Prospectus has been or will be approved or disapproved by the United States Securities and Exchange Commission or by the securities commissions of any state or other jurisdiction of the United States or any other regulatory authority, and none of the foregoing authorities or any securities commission has passed upon or endorsed the merits of such securities or documents or the accuracy or adequacy of this announcement or any other such document. Any representation to the contrary is a criminal offence in the United States.

 

No offer or invitation to purchase or subscribe for, or any solicitation to purchase or subscribe for, any securities will be made in any jurisdiction in which such an offer or solicitation is unlawful. The information contained in this announcement is not for release, publication or distribution to persons in the United States or Australia, Canada, Japan or the Republic of South Africa, and should not be distributed, forwarded to or transmitted in or into any jurisdiction, where to do so might constitute a violation of local securities laws or regulations.

 

The distribution of this announcement into jurisdictions other than the United Kingdom may be restricted by law, and, therefore, persons into whose possession this announcement comes should inform themselves about and observe any such restrictions. Any failure to comply with any such restrictions may constitute a violation of the securities laws of such jurisdiction. In particular, subject to certain exceptions, neither this announcement nor the Prospectus should be distributed, forwarded to or transmitted in or into the United States, Australia, Canada, Japan or the Republic of South Africa or any other jurisdiction where to do so might constitute a violation of local securities laws or regulations.

 

The contents of this announcement are not to be construed as legal, business, financial or tax advice. Each Shareholder or prospective investor should consult his, her or its own legal adviser, business adviser, financial adviser or tax adviser for legal, financial, business or tax advice.

 

Notice to all investors

 

Barclays Bank PLC, acting through its investment bank ("Barclays"), which is authorised by the Prudential Regulation Authority and regulated in the United Kingdom by the Financial Conduct Authority and the Prudential Regulation Authority, is acting exclusively for the Company and no one else in connection with the Admission of the Tranche 1 Consideration Shares and the Placing Shares and will not be responsible to anyone other than the Company for providing the protections afforded to clients of Barclays nor for providing advice in relation to Admission of the Tranche 1 Consideration Shares and the Placing Shares or any transaction, matter or arrangement referred to in this announcement or in the Prospectus.

 

J.P. Morgan Securities plc (which conducts its UK investment banking business as "J.P. Morgan Cazenove") is authorised by the Prudential Regulation Authority and regulated by the Prudential Regulation Authority and Financial Conduct Authority. J.P. Morgan Cazenove is acting exclusively for the Company and no one else in connection with the Strategic Cooperation and will not be responsible to anyone other than Aston Martin Lagonda Global Holdings plc for providing the protections afforded to clients of J.P. Morgan Cazenove nor for providing advice to any person in relation to the Strategic Cooperation or any matter or arrangement referred to in this announcement or in the Prospectus.

 

None of Barclays or J.P. Morgan Cazenove, nor any of their respective subsidiaries, branches or affiliates, nor any of their respective directors, officers or employees owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Barclays or J.P. Morgan Cazenove in connection with this Announcement, any statement contained herein, or otherwise.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCGCBDBCDDDGGL
Date   Source Headline
14th Sep 20229:49 amRNSHolding(s) in Company
14th Sep 20229:46 amRNSHolding(s) in Company
14th Sep 20227:00 amRNSRights Issue offer period amended
13th Sep 20229:00 amRNSHolding(s) in Company
12th Sep 20227:00 amRNSAdmission of Nil Paid Rights
9th Sep 20227:00 amRNSAdmission of placing shares & total voting rights
8th Sep 202211:32 amRNSResult of General Meeting
5th Sep 202212:28 pmRNSPublication of Prospectus
5th Sep 20227:00 amRNS4 for 1 c.£575.8 million Rights Issue
22nd Aug 20227:00 amRNSCircular and Notice of General Meeting
29th Jul 20227:00 amRNSHalf-year Report
15th Jul 20227:00 amRNSProposed New Equity Financing and Investment
1st Jul 20223:37 pmRNSHolding(s) in Company
1st Jul 202211:38 amRNSHolding(s) in Company
30th Jun 20223:31 pmRNSStatement Regarding Media Commentary
20th Jun 20221:20 pmRNSCompany Secretary Change
14th Jun 20227:00 amRNSDirector/PDMR Shareholding
25th May 202212:04 pmRNSResult of AGM
11th May 20227:00 amRNSHolding(s) in Company
4th May 20227:01 amRNS1st Quarter Results
4th May 20227:00 amRNSAppointment of New Chief Executive Officer
3rd May 20227:00 amRNSNew Chief Financial Officer Joins Board
28th Apr 20223:14 pmRNSHolding(s) in Company
25th Apr 20222:08 pmRNSNotice of AGM
20th Apr 202212:19 pmRNSDirector Declaration
31st Mar 20227:00 amRNSDirector/PDMR Shareholding
14th Mar 20227:02 amRNSChief Financial Officer Board Appointment Date
14th Mar 20227:00 amRNSPublication of 2021 Annual Report and Accounts
28th Feb 20227:00 amRNSDirector/PDMR Shareholding
23rd Feb 20227:00 amRNSFinal Results
2nd Feb 20227:00 amRNSHolding(s) in Company
14th Jan 20227:00 amRNSDirectorate Change
7th Jan 20227:00 amRNSFY 2021 Trading Update
31st Dec 20217:00 amRNSTotal Voting Rights
21st Dec 20217:00 amRNSDirector/PDMR Shareholding
17th Dec 202110:01 amRNSDirector/PDMR Shareholding
2nd Dec 20213:07 pmRNSDirector/PDMR Shareholding
2nd Dec 20217:00 amRNSDirectorate Change
1st Dec 202110:19 amRNSAdditional Listing
29th Nov 202110:53 amRNSDirector/PDMR Shareholding
24th Nov 20212:00 pmRNSDirector/PDMR Shareholding
12th Nov 202110:30 amRNSDirector/PDMR Shareholding
8th Nov 202110:49 amRNSDirector/PDMR Shareholding
4th Nov 20217:05 amRNSResults for the nine months to 30 September 2021
29th Oct 202110:02 amRNSTotal Voting Rights
1st Oct 202112:08 pmRNSTotal Voting Rights
31st Aug 202110:37 amRNSTotal Voting Rights
12th Aug 202110:58 amRNSDirector/PDMR Shareholding
3rd Aug 20212:35 pmRNSDirector/PDMR Shareholding
29th Jul 202110:00 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.